BeStock  
Stocks › Biotechnology › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3471Biotechnology
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$299,000.00-43.5% YoY
Operating profit-$10.27M-23.9% YoY
Net profit$59.12M+863.6% YoY
Diluted EPS$0.30+850.0% YoY
Free cash flow$239.81M+4,222.6% YoY
Operating cash flow$239.81M

Revenue, last 8 quarters

$1.6MDec '24$1.8MMar '25$10.7MJun '25$529.0KSep '25$1.1MDec '25$179.1MMar '26$1.0MJun '26$299.0KSep '26

Net profit, last 8 quarters

$-12.5MDec '24$-24.5MMar '25$2.5MJun '25$-7.7MSep '25$-3.8MDec '25$169.7MMar '26$-5.1MJun '26$59.1MSep '26

Diluted EPS by quarter

-0.07Dec '24-0.13Mar '250.01Jun '25-0.04Sep '25-0.01Dec '250.87Mar '26-0.03Jun '260.30Sep '26

Free cash flow by quarter

$-10.4MDec '24$-13.4MMar '25$-15.7MJun '25$-5.8MSep '25$-4.7MDec '25$-8.1MMar '26$-6.0MJun '26$239.8MSep '26

Annual revenue

$6.9MFY20$11.0MFY21$39.0MFY22$18.1MFY23$6.2MFY24$14.1MFY25

Profitability & balance sheet

Operating margin80.1%
Net margin121.2%
Return on equity269.6%
Return on assets100.6%
Return on invested capital264.0%
Current ratio1.40
Liabilities / assets74.8%
Cash & investments$337.49M
Total debt$0.00
Net cash (debt)$337.49M
Free cash flow / sales121.8%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $299,000.00 $1.01M $179.13M $14.08M $1.05M
Total Operating Revenue $299,000.00 $1.01M $179.13M $14.08M $1.05M
Operating Expense $10.57M $6.77M $10.01M $41.13M $8.70M
Selling and Admin Expenses $7.96M $3.87M $5.89M $15.89M $3.69M
-General & Admin Expense $7.96M $3.87M $5.89M $15.89M $3.69M
Research & Development $2.62M $2.90M $4.12M $25.24M $5.01M
Operating Profit -$10.27M -$5.75M $169.12M -$27.05M -$7.64M
Net Non-Operating Interest Income (Expense) $2.36M $824,000.00 $798,000.00 $3.97M $859,000.00
Non-Operating Interest Income $2.37M $842,000.00 $815,000.00 $4.07M $877,000.00
Non-Operating Interest Expense $11,000.00 $18,000.00 $17,000.00 $97,000.00 $18,000.00
Other Income (Expense) $67.03M -$216,000.00 -$220,000.00 -$10.42M $3.03M
Gain on Sale of Security $67.25M -$3,000.00 -$11,000.00 $14,000.00 $1,000.00
Special Income (Charges) -$221,000.00 -$213,000.00 -$209,000.00 -$10.44M $3.03M
-Less:Restructuring and Mergern & Acquisition $221,000.00 $213,000.00 $209,000.00 $11.11M -$2.35M
Pretax Profit $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Net Profit $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Profit from Continuing Operations $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Net Income to Parent Company $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Net Income to Common Stockholders $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Basic EPS $0.30 -$0.03 $0.88 -$0.17 -$0.01
Diluted EPS $0.30 -$0.03 $0.87 -$0.17 -$0.01
-Gain on Sale of Property/Plant/Equipment – – – $674,000.00 –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $339.70M $274.03M $277.16M $94.62M $94.62M
Total Current Assets $339.57M $273.88M $277.01M $94.46M $94.46M
Cash and Cash Equivalents & Short-Term Investments $337.49M $92.63M $95.23M $91.47M $91.47M
-Cash and Cash Equivalents $264.19M $19.17M $23.71M $18.01M $18.01M
-Short Term Investments $73.30M $73.45M $71.52M $73.46M $73.46M
Receivables $792,000.00 $179.74M $180.05M $1.45M $1.45M
-Accounts Receivable $792,000.00 $369,000.00 $1.31M $1.45M $1.45M
Other Current Assets $1.29M $1.52M $1.73M $1.54M $1.54M
Total Non-Current Assets $131,000.00 $142,000.00 $153,000.00 $162,000.00 $162,000.00
Net PPE $0.00 $10,000.00 $22,000.00 $32,000.00 $32,000.00
-Gross PPE $245,000.00 $245,000.00 $246,000.00 $245,000.00 $245,000.00
-Accumulated Depreciation -$245,000.00 -$235,000.00 -$224,000.00 -$213,000.00 -$213,000.00
Other Non-Current Assets $131,000.00 $132,000.00 $131,000.00 $130,000.00 $130,000.00
Total Liabilities $253.95M $15.29M $16.99M $18.04M $18.04M
Total Current Liabilities $241.93M $3.36M $5.11M $6.01M $6.01M
Payables $320,000.00 $373,000.00 $1.46M $1.17M $1.17M
-Accounts Payable $320,000.00 $373,000.00 $1.46M $1.17M $1.17M
Current Accrued Expenses $11.19M $2.32M $2.77M $3.65M $3.65M
Short-Term Debt and Capital Lease Obligation $328,000.00 $514,000.00 $631,000.00 $547,000.00 $547,000.00
-Current Capital Lease Obligation $328,000.00 $514,000.00 $631,000.00 $547,000.00 $547,000.00
Other Current Liabilities $230.10M $160,000.00 $245,000.00 $640,000.00 $640,000.00
Total Non-Current Liabilities $12.02M $11.93M $11.88M $12.04M $12.04M
Long Term Debt and Capital Lease Obligation $0.00 $0.00 $0.00 $199,000.00 $199,000.00
-Long Term Capital Lease Obligation $0.00 $0.00 $0.00 $199,000.00 $199,000.00
Other Non-Current Liabilities $12.02M $11.93M $11.88M $11.84M $11.84M
Total Equity $85.75M $258.73M $260.18M $76.58M $76.58M
Stockholders' Equity $85.75M $258.73M $260.18M $76.58M $76.58M
Capital Stock $1.46B $1.45B $1.44B $1.42B $1.42B
-Common Stock $1.46B $1.45B $1.44B $1.42B $1.42B
Additional Paid-In Capital -$167.33M $74.32M $74.26M $83.32M $83.32M
Retained Earnings -$1.16B -$1.22B -$1.21B -$1.38B -$1.38B
Gains/Losses Not Affecting Retained Earnings -$48.29M -$48.24M -$48.20M -$48.10M -$48.10M
-Other Receivables – $179.37M $178.74M – –
Current Deferred Liabilities – – – $0.00 $0.00
Non-Current Deferred Liabilities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $239.81M -$6.02M -$8.11M -$39.64M -$4.68M
Net cash flow from continuing operations $239.81M -$6.02M -$8.11M -$39.64M -$4.68M
Net Income from Continuing Operations $59.12M -$5.14M $169.70M -$33.50M -$3.76M
Depreciation & Depletion & Amortization $10,000.00 $11,000.00 $11,000.00 $363,000.00 $11,000.00
Other Non-Cash Items $91,000.00 $46,000.00 $45,000.00 -$3.22M -$2.90M
Change in Working Capital $179.80M -$2.24M -$178.87M -$10.02M $1.80M
-Change in Receivables $178.95M -$179.46M $1.16M $1.38M -$129,000.00
-Change in Prepaid Assets $233,000.00 $215,000.00 -$195,000.00 $1.70M $1.30M
-Change in Payables and Accrued Expense $806,000.00 -$1.62M -$985,000.00 -$2.11M $806,000.00
-Change in Other Current Liabilities -$185,000.00 -$113,000.00 -$105,000.00 -$557,000.00 -$177,000.00
Net cash flow from investing $504,000.00 -$1.66M $2.20M $15.58M -$1.36M
Net Cash Flow from Continuing Investing Activities $504,000.00 -$1.66M $2.20M $15.58M -$1.36M
Net PPE Purchase and Sale $0.00 – – $364,000.00 $355,000.00
Net Investment Purchase and Sale $504,000.00 -$1.66M $2.20M $15.22M -$1.72M
Financing Cash Flow $4.71M $3.15M $11.62M $5.72M $1.64M
Net Cash Flow from Continuing Financing Activities $4.71M $3.15M $11.62M $5.72M $1.64M
Proceeds from Stock Option Exercised $4.71M $3.15M $11.62M $5.72M $1.64M
Ending Cash Balance $264.19M $19.17M $23.71M $18.01M $18.01M
Net Change in Cash $245.02M -$4.53M $5.71M -$18.34M -$4.40M
Beginning Cash Balance $19.17M $23.71M $18.01M $36.33M $22.41M
Effect of Exchange Rate Changes -$2,000.00 -$4,000.00 -$10,000.00 $14,000.00 $1,000.00
Free Cash Flow $239.81M -$6.02M -$8.11M -$39.64M -$4.68M
-Change In Other Working Capital – – -$178.74M -$10.43M $0.00
Net Other Investing Changes – – -$1,000.00 – –
Gain/Loss from Continuing Operations – – – -$674,000.00 –
Net Common Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on ABUS.

Sign in to join the discussion.

Scroll to Top